Cargando…
Ivermectin, a potential anticancer drug derived from an antiparasitic drug
Ivermectin is a macrolide antiparasitic drug with a 16-membered ring that is widely used for the treatment of many parasitic diseases such as river blindness, elephantiasis and scabies. Satoshi ōmura and William C. Campbell won the 2015 Nobel Prize in Physiology or Medicine for the discovery of the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114/ https://www.ncbi.nlm.nih.gov/pubmed/32971268 http://dx.doi.org/10.1016/j.phrs.2020.105207 |
_version_ | 1783584751873949696 |
---|---|
author | Tang, Mingyang Hu, Xiaodong Wang, Yi Yao, Xin Zhang, Wei Yu, Chenying Cheng, Fuying Li, Jiangyan Fang, Qiang |
author_facet | Tang, Mingyang Hu, Xiaodong Wang, Yi Yao, Xin Zhang, Wei Yu, Chenying Cheng, Fuying Li, Jiangyan Fang, Qiang |
author_sort | Tang, Mingyang |
collection | PubMed |
description | Ivermectin is a macrolide antiparasitic drug with a 16-membered ring that is widely used for the treatment of many parasitic diseases such as river blindness, elephantiasis and scabies. Satoshi ōmura and William C. Campbell won the 2015 Nobel Prize in Physiology or Medicine for the discovery of the excellent efficacy of ivermectin against parasitic diseases. Recently, ivermectin has been reported to inhibit the proliferation of several tumor cells by regulating multiple signaling pathways. This suggests that ivermectin may be an anticancer drug with great potential. Here, we reviewed the related mechanisms by which ivermectin inhibited the development of different cancers and promoted programmed cell death and discussed the prospects for the clinical application of ivermectin as an anticancer drug for neoplasm therapy. |
format | Online Article Text |
id | pubmed-7505114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75051142020-09-23 Ivermectin, a potential anticancer drug derived from an antiparasitic drug Tang, Mingyang Hu, Xiaodong Wang, Yi Yao, Xin Zhang, Wei Yu, Chenying Cheng, Fuying Li, Jiangyan Fang, Qiang Pharmacol Res Review Ivermectin is a macrolide antiparasitic drug with a 16-membered ring that is widely used for the treatment of many parasitic diseases such as river blindness, elephantiasis and scabies. Satoshi ōmura and William C. Campbell won the 2015 Nobel Prize in Physiology or Medicine for the discovery of the excellent efficacy of ivermectin against parasitic diseases. Recently, ivermectin has been reported to inhibit the proliferation of several tumor cells by regulating multiple signaling pathways. This suggests that ivermectin may be an anticancer drug with great potential. Here, we reviewed the related mechanisms by which ivermectin inhibited the development of different cancers and promoted programmed cell death and discussed the prospects for the clinical application of ivermectin as an anticancer drug for neoplasm therapy. Elsevier Ltd. 2021-01 2020-09-21 /pmc/articles/PMC7505114/ /pubmed/32971268 http://dx.doi.org/10.1016/j.phrs.2020.105207 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Tang, Mingyang Hu, Xiaodong Wang, Yi Yao, Xin Zhang, Wei Yu, Chenying Cheng, Fuying Li, Jiangyan Fang, Qiang Ivermectin, a potential anticancer drug derived from an antiparasitic drug |
title | Ivermectin, a potential anticancer drug derived from an antiparasitic drug |
title_full | Ivermectin, a potential anticancer drug derived from an antiparasitic drug |
title_fullStr | Ivermectin, a potential anticancer drug derived from an antiparasitic drug |
title_full_unstemmed | Ivermectin, a potential anticancer drug derived from an antiparasitic drug |
title_short | Ivermectin, a potential anticancer drug derived from an antiparasitic drug |
title_sort | ivermectin, a potential anticancer drug derived from an antiparasitic drug |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114/ https://www.ncbi.nlm.nih.gov/pubmed/32971268 http://dx.doi.org/10.1016/j.phrs.2020.105207 |
work_keys_str_mv | AT tangmingyang ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug AT huxiaodong ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug AT wangyi ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug AT yaoxin ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug AT zhangwei ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug AT yuchenying ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug AT chengfuying ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug AT lijiangyan ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug AT fangqiang ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug |